Tambotatug Pelitecan Delivers a Major Survival Gain in Relapsed SCLC: TAISHAN-302 Establishes B7-H3 as a Therapeutic Target
Sep 14, 2026
View online
Tambotatug Pelitecan Delivers a Major Survival Gain in Relapsed SCLC: TAISHAN-302 Establishes B7-H3 as a Therapeutic Target
FDA Approves Floretyrosine F 18 for PET Imaging in Glioma
Pavlos Msaouel: Rethinking Clinical Trial Design for Rare RCC Subtypes
Cancer Immunotherapy: 2016 vs 2026
Dario Trapani: Discussing Innovation, Access and Sustainability in European Oncology
The State of Oncology in 2026 With ZS
10 Must-Read Posts In GI Oncology This Week
FIGHT KIDS CANCER General Paediatric Cancer Grants 2026–2027
Blood Cancer United Translational Research Program 2026–2027
ESSO Hands-On Course on the Minimally Invasive Management of Peritoneal Surface Malignancies
58th Congress of the International Society of Paediatric Oncology (SIOP 2026)
The Voice of Oncology
Unsubscribe
|
Manage subscription
OncoDaily, P53 Inc.
867 Boylston Street, 5th Floor, Suite 1094, Boston, MA 02116
Copyright (C) 2023-2026. OncoDaily, P53 Inc. All rights reserved.
